Trigeminal Evoked Responses to Improve Rhizotomy
Launched by UNIVERSITY OF MINNESOTA · Feb 17, 2023
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a technique called Trigeminal Somatosensory Evoked Potentials (TSEPs) to see if it can help improve a surgical procedure called rhizotomy for people suffering from trigeminal neuralgia (TGN). TGN is a condition that causes severe, shock-like facial pain. The researchers want to find out if using TSEPs during the rhizotomy procedure is practical and beneficial for patients. This study will include adults aged 18 and older who are scheduled to have the rhizotomy surgery for their facial pain.
If you or a loved one has been diagnosed with TGN and are planning to undergo rhizotomy, you might be eligible to participate in this trial. Participants will undergo the standard rhizotomy procedure, and the researchers will monitor the TSEPs to gather data. It's important to note that patients with unclear facial pain origins or certain other pain conditions will not be eligible for this study. This trial is currently recruiting participants, and it offers a chance to contribute to understanding and potentially improving treatment for TGN.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults of 18 years or older
- • Scheduled to undergo percutaneous rhizotomy for facial pain
- Exclusion Criteria:
- • For TGN: Facial pain of unclear origin (i.e. not clearly TGN pain) or Rhizotomy procedure canceled
- • For Healthy control: Diagnosis or history of facial pain such as TMD or TGN, History of migraine, History of any functional pain disorder: fibromyalgia, IBS, CRPS or Recent chronic pain (within last month)
About University Of Minnesota
The University of Minnesota is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on interdisciplinary collaboration, the university leverages its extensive resources and expertise to conduct cutting-edge studies aimed at improving patient outcomes and addressing critical health challenges. Its robust clinical trial program emphasizes ethical standards, patient safety, and scientific rigor, contributing to the development of novel therapies and interventions that enhance medical practice and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Minneapolis, Minnesota, United States
Patients applied
Trial Officials
David P Darrow, MD
Principal Investigator
University of Minnesota
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials